Navigation Links
Akela Pharma provides corporate update
Date:12/20/2007

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, Dec. 20 /PRNewswire-FirstCall/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that due to unfavorable market conditions, particularly in the small and micro-cap sector, it has decided to abandon its US public offering initiative. The Company is currently contemplating other financing options. It is still the Company's intention to list its shares on a US exchange.

Akela also announces it has already started to implement significant cost reduction measures to bring its cash burn rate in line with its current and expected financial resources. The Company will primarily focus its R&D activities on its core programs. PharmaForm, the Company's drug formulation and manufacturing subsidiary located in Austin, Texas, is currently experiencing substantial growth, and is expected to contribute towards the Company's operating cash flow in the near term.

"Although the latest unfavorable market conditions did not allow us to complete our US public offering as originally planned, we remain extremely confident about the appeal and commercial potential of our products and platforms. We have aligned our corporate focus with our financial resources to ensure optimal returns on our core activities" said Dr Halvor Jaeger, CEO of Akela Pharma Inc.

About Akela Pharma Inc.

Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation and pain markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.

Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 11.7 million shares outstanding.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of Akela Pharma Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.


'/>"/>
SOURCE AKELA PHARMA INC.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
2. Akela Pharma Inc. Completes Share Consolidation
3. AKELA Pharma Inc. announces U.S. public offering and proposed listing
4. Akela Pharma reports results for third quarter of fiscal 2007
5. Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial
6. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
7. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. ... of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death ... podcasted thereafter . Dr. Bernie Siegel, author of a plethora of essential ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine ... announce one of their physicians has been invited to be a featured speaker at ... Practice Review conference on April 30, 2016. , Dr. R. Scott McPherson, a ...
(Date:4/29/2016)... ... 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 ... skin cancer deaths. More than 10,000 people are expected to die of melanoma this year. ... is the one of the most commonly diagnosed cancers in young women. A recent breakthrough ...
(Date:4/29/2016)... ... 29, 2016 , ... Jvion, the market leader in clinical ... Eastside Partners, with participation from existing investor Martin Ventures. The funds will ... technology and product roadmap. , “Jvion is experiencing significant growth and ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Nike Softball ... softball camp from July 24th – 27th for girls aged 10-18. All facets of ... held at the beautiful Clark V. Whited Complex, one of the finest softball facilities ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016 Shire plc ... Jeff Poulton , Chief Financial Officer, will present at the ... Boston, MA on Wednesday, May 04, 2016, 10:00 ... will be available on the Presentations and Webcasts section of ... of the webcast will be available on this same website ...
(Date:4/27/2016)... , April 27, 2016 ... over USD 2.14 billion by 2022, according to ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ... advancement affecting the efficiency and accuracy delivered by ... persistent demand for novel urinalysis instruments and consumables. ...
(Date:4/26/2016)... , April 26, 2016 Diplomat Pharmacy, ... of Jennifer Hagerman , Pharm D., to Vice ... growing role at Diplomat, Hagerman will continue to lead ... company that delivers custom education and training to Diplomat ... specialty pharmacy industry. Diplomat University also houses the quality ...
Breaking Medicine Technology: